MTE #17 Refractory Immune-Mediated Liver Injury from Checkpoint Inhibitors: When to Bring Out the Big Guns?

Nov 09 2025
Convention Center: Room 144C, Level 1
7:00 AM - 7:45 AM
Ticketed Event

World Class Speakers

ML
Discussion Leader

Michael Li, MD

The University of California, San Francisco
Lily Dara, MD
Discussion Leader

Lily Dara, MD

University of Southern California

Description

Hepatologists are often consulted by our oncology colleagues when patients develop immune-mediated liver injury from checkpoint Inhibitors (ILICI) that are steroid refractory and resistant. Speakers in this session discuss the exploratory second-line and third-line treatment options that have been succesfully used in case series, case reports, and in other immune-mediated adverse events such as colitis, pneumonitis, dermatitis, and myocarditis.

Journey Maps

Objectives

  • Define steroid-refractory and steroid-resistant immune-mediated liver injury from checkpoint inhibitors (ILICI).
  • Describe the existing evidence for use of mycophenolate, the most commonly used second-line therapy for ILICI.
  • List third-line treatment options that have been successfully used in hepatitis/ILICI and other immune-related adverse events.